Moody Aldrich Partners LLC Raises Position in Kura Oncology, Inc. (NASDAQ:KURA)

Moody Aldrich Partners LLC boosted its position in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 42.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 143,587 shares of the company's stock after buying an additional 42,712 shares during the quarter. Moody Aldrich Partners LLC owned approximately 0.18% of Kura Oncology worth $1,251,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Suvretta Capital Management LLC grew its position in shares of Kura Oncology by 8.2% during the 3rd quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company's stock valued at $149,535,000 after acquiring an additional 583,155 shares during the period. Alethea Capital Management LLC grew its holdings in Kura Oncology by 108.2% in the third quarter. Alethea Capital Management LLC now owns 553,542 shares of the company's stock valued at $10,816,000 after purchasing an additional 287,636 shares during the period. Point72 Asset Management L.P. acquired a new stake in Kura Oncology in the third quarter valued at approximately $3,695,000. Barclays PLC increased its position in shares of Kura Oncology by 104.5% in the third quarter. Barclays PLC now owns 165,484 shares of the company's stock valued at $3,234,000 after buying an additional 84,563 shares in the last quarter. Finally, AQR Capital Management LLC raised its stake in shares of Kura Oncology by 251.5% during the 2nd quarter. AQR Capital Management LLC now owns 81,655 shares of the company's stock worth $1,681,000 after buying an additional 58,422 shares during the period.

Analysts Set New Price Targets

KURA has been the subject of several recent analyst reports. Stifel Nicolaus lowered shares of Kura Oncology from a "buy" rating to a "hold" rating and cut their price target for the stock from $26.00 to $19.00 in a report on Monday, October 14th. Wedbush reissued an "outperform" rating and set a $37.00 target price on shares of Kura Oncology in a research note on Monday, November 4th. Bank of America reduced their price target on shares of Kura Oncology from $36.00 to $29.00 and set a "buy" rating for the company in a research report on Friday, November 22nd. TD Cowen reiterated a "buy" rating on shares of Kura Oncology in a report on Thursday, November 21st. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Kura Oncology in a report on Monday, December 9th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $27.38.

Insider Activity at Kura Oncology

In related news, insider Mollie Leoni sold 4,963 shares of the firm's stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the sale, the insider now directly owns 88,253 shares of the company's stock, valued at approximately $694,551.11. This trade represents a 5.32 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Thomas James Doyle sold 4,949 shares of the business's stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $38,948.63. Following the completion of the sale, the senior vice president now owns 88,193 shares in the company, valued at approximately $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 12,255 shares of company stock valued at $100,739. 5.50% of the stock is owned by company insiders.

Kura Oncology Price Performance

Shares of KURA stock traded down $0.12 during trading hours on Friday, reaching $7.91. The company had a trading volume of 1,362,535 shares, compared to its average volume of 1,345,422. Kura Oncology, Inc. has a 12-month low of $6.98 and a 12-month high of $24.17. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The company has a market capitalization of $615.08 million, a price-to-earnings ratio of -3.35 and a beta of 0.81. The stock has a fifty day moving average of $8.97 and a 200-day moving average of $15.42.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.01. During the same period in the previous year, the firm earned ($0.50) earnings per share. On average, equities analysts anticipate that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.